MC2-32 Hidradenitis Suppurativa
(Oral)
About Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a debilitating, inflammatory disorder with a high, unmet medical need. It is characterized by chronic, painful nodules, abscesses and suppurating sinus tracts that in the most severe form cause significant scarring. Commonly affected body locations include the axillary, infra- and intermammary, inguinal, perineal and gluteal regions. Patients may experience pain, itching, malodour, and a burning sensation. For many patients the disease has a huge impact on their quality of life.
The female/male ratio is 3:1 in the Caucasian population although this may not be the same in the Asian and African population. HS occurs most commonly in the third and fourth decades of life although also children can have the disease. It can be difficult to diagnose HS and there is an average delay of 7-10 years between disease onset and diagnosis.
The disease mechanisms that cause HS are complex and not yet fully understood. However, HS is sometime described as an apocrinitis because blockage and inflammation in the apocrine glands around the hair follicles seems to be an important initial step in the disease pathogenesis. This results in increased expression of multiple pro-inflammatory cytokines and activation of a number of signaling pathways that together cause the skin manifestations seen in HS patients.
Treatment options are still limited and there remains a high unmet medical need.
Clinical Stage
Phase 2a completed.
Phase 2b in planning.
MC2-32
Active ingredient: HSP90 inhibitor
Indication: Hidradenitis Suppurativa
Pipeline
